---
title: "Lilly, South Korean Drug Maker Partnering to Commercialize Prospective Liver Disease Treatment"
date: "2025-02-10 22:33:59"
summary: "Eli Lilly &amp; Co. has signed a global licensing agreement to commercialize RNAi genetic technology developed by Olix Pharmaceuticals, OliX said on Monday. The agreement requires Lilly to help fund early-stage testing of the South Korean biotechnology firm's OLX75016 product candidate for metabolic-associated steatohepatitis and other cardiometabolic indications, OliX said...."
categories:
  - "MT Newswires"
lang:
  - "en"
translations:
  - "en"
tags:
  - "MT Newswires"
menu: ""
thumbnail: ""
lead: ""
comments: false
authorbox: false
pager: true
toc: false
mathjax: false
sidebar: "right"
widgets:
  - "search"
  - "recent"
  - "taglist"
---

Eli Lilly & Co. has signed a global licensing agreement to commercialize RNAi genetic technology developed by Olix Pharmaceuticals, OliX said on Monday.

The agreement requires Lilly to help fund early-stage testing of the South Korean biotechnology firm's OLX75016 product candidate for metabolic-associated steatohepatitis and other cardiometabolic indications, OliX said.

OliX said it will receive an unspecified payment from Lilly to complete the early-stage trial of OLX75016, which is currently underway in Australia.

Other details of the agreement were not immediately disclosed.

[MT Newswires](https://www.tradingview.com/news/mtnewswires.com:20250210:A3313579:0/)
